127 related articles for article (PubMed ID: 20210247)
1. Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report.
Tisman G
Tumori; 2009; 95(6):804-7. PubMed ID: 20210247
[TBL] [Abstract][Full Text] [Related]
2. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
Stemmler HJ; Stieber P; Lässig D; Heinemann V
Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
[TBL] [Abstract][Full Text] [Related]
3. Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
Asakura H; Takashima H; Mitani M; Haba R; Seo R; Yokoe K; Toyama Y; Ohkawa M
Int J Clin Oncol; 2005 Aug; 10(4):285-8. PubMed ID: 16136377
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
5. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
6. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
7. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
[TBL] [Abstract][Full Text] [Related]
8. [A pilot study of trastuzumab and vinorelbine-combined therapy for metastatic breast cancer].
Onishi I; Tsugawa K; Nakamura M; Nishimura G; Fujimura T; Taniya T; Kayahara M; Shimizu K; Ohta T; Miwa K
Gan To Kagaku Ryoho; 2004 May; 31(5):743-6. PubMed ID: 15170984
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
Schilling G; Bruweleit M; Harbeck N; Thomssen C; Becker K; Hoffmann R; Villena C; Schütte M; Hossfeld DK; Bokemeyer C; de Wit M
Invest New Drugs; 2009 Apr; 27(2):166-72. PubMed ID: 18696011
[TBL] [Abstract][Full Text] [Related]
10. Combination of trastuzumab and vinorelbine in metastatic breast cancer.
Suzuki Y; Tokuda Y; Saito Y; Ohta M; Tajima T
Jpn J Clin Oncol; 2003 Oct; 33(10):514-7. PubMed ID: 14623919
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
Jahanzeb M; Mortimer JE; Yunus F; Irwin DH; Speyer J; Koletsky AJ; Klein P; Sabir T; Kronish L
Oncologist; 2002; 7(5):410-7. PubMed ID: 12401903
[TBL] [Abstract][Full Text] [Related]
12. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
[TBL] [Abstract][Full Text] [Related]
13. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
[TBL] [Abstract][Full Text] [Related]
14. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Maciá Escalante S; Rodríguez Lescure A; Pons Sanz V; Martínez Banaclocha N; Guillén Ponce C; Carrato Mena A
Clin Transl Oncol; 2006 Oct; 8(10):761-3. PubMed ID: 17074677
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
18. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
19. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
Heinemann V; Di Gioia D; Vehling-Kaiser U; Harich HD; Heinrich B; Welt A; Ziske C; Deutsch G; Pihusch R; Kölbl H; Hegewisch-Becker S; Michl M; Stemmler HJ
Ann Oncol; 2011 Mar; 22(3):603-608. PubMed ID: 20724574
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience.
Di Lauro V; Murrone A; Bidoli E; Magri MD; Crivellari D; Veronesi A
Tumori; 2008; 94(4):464-8. PubMed ID: 18822679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
